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Application of PDT for Uterine Cervical Cancer
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H. IWABUCHI, H. SAKUNAGA, M. SAKAMOTO, T. SUGISHITA and Y. TENJIN
Department of Gynecology, Sasaki Institute, Kyoundo Hospital, 1-8 Kanda, Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan
We have been performingPDT using Excimer Dye Laser (EDL) orYAG-OPO laser, a type
oflow power laser, both ofwhich have a considerably higher degree of tissue penetration even
when compared to PDT using Argon Dye Laser (ADL).
PDT is a relatively simple procedure without any bleeding and does not require anesthesia
since it causes no pain. PDT is performed 48 h after intravenous injection of 1.5-2.0 mg/kg
ofPHE (Photofrin(R)). Precise spot irradiation is possible using a colposcope with an optical
laser path. We also use a cervical probe which enables photoirradiation of the entire cervical
canal.
We have performed PDT on 131 cases (95 CIS, 31 dysplasia, 1 vulval dysplasia (VIN),
3 squamous cell carcinoma, microinvasion, and 1 CIS +endocervical adenocarcinoma,
microinvasion). Ofthese cases, 127 became CR (96.9%). The first CR case was 10 years ago
and no recurrence has been observed yet.
PDT is extremely effective to preserve fertility. Except for sensitive reactions to sunlight,
there are no noticeable side effects or difficulties related to pregnancy or delivery. We expect
that in the near future PDT will be performed using diode lasers and without hospitalization
due to new photosensitizers which have shorter retention times.
Keywords: Excimer dye laser, Photodynamic therapy (PDT), Photofrin(R) (PHE),
Uterine cervical cancer, YAG-OPO laser
INTRODUCTION
The discovery rates ofdysplasia and CIS for cervical
cancer has increased due to the recent awareness
about and availability of cervical cancer examina-
tions. As a result, there has been an increase in the
number of patients and a decrease in the average
age of patients. For these patients, it is desirable to
perform operations to preserve fertility with respect
to the quality of life of each patient.
As an operation to preserve fertility, conventional
conization by cold knife (Sturmdorf operation) has
traditionally been employed, but recent laser ther-
apy using high-power lasers such as CO2 laser,YAG
laser and LEEP (Loop Electrosurgical Excision
Procedure) are now frequently administered. It
should be noted that these treatments are sometimes
accompanied by unexpected bleeding, and since the
treatment is accompanied by pain, anesthesia is
necessary in most cases. In addition, a large portion
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FIGURE Excimer dye laser (EDL). FIGURE 2 YAG-OPO laser.
ofthe cervical glands critical for reproduction tends
to be lost during the operation.
To meet the demands ofthe increasing number of
younger patients wanting to preserve fertility and
to accommodate high risk patients, elderly patients,
and those who refuse surgery, PDT has been used
as a breakthrough method. PDT can be performed
without anesthesia since there is no pain. Further,
there is no bleeding with PDT, fertility can be pre-
served while leaving the cervix relatively intact, and
there are no negative effects on pregnancy and
delivery.
PDT, with the use of Excimer Dye Laser (EDL)
(Fig. 1) a type oflow power laser, has a considerably
higher degree of tissue penetration, even compared
to PDT using Argon Dye Laser (ADL). Also, PDT
using EDL can manage glandular involvement of
CIN, and its special feature of selective destruction
ofmalignant cells with little effect on normal tissue
is noteworthy. Beginning in 1995, PDT usingYAG-
OPO laser (Fig. 2) with a variable laser wavelength
has been performed.
MATERIALS AND METHODS
Photosensitizer: PHE
Tumor affinity photosensitive substance: Porphyrin
dimerto octomermixed substance. Maincomponent
is dimer DHE (dehematoporphyrin ester/ether)
a drug of freeze-dried powder consistency with
a dark red color containing 75mg PHE per vial
(provided by Lederle (Japan), Ltd.).PDT FOR CERVICAL CANCER 185
Laser Delivery Systems: EDL and
YAG-OPO Laser
TheEDL is a low energy power laser, and its 630nm
wavelength dye laser is generated when rhodamine
640 pigment solution is irradiated by 308 nm ultra-
violet rays generated by an XeC1Excimer laser. The
laser wavelength is 630-635 nm, width of pulse is
10+ 5 nsec, and pulse radiation energy is 4-5 mJ!
pulse maximum. Pulse repeated frequency is 40 Hz
in normal cases (interchangeable to 40, 60, and
80 Hz) (Fig. 1).
YAG-OPO laser is a PDT laser that has an optic
parametric oscillator (OPO), Q switch pulse YAG
laser intensifier installed. Laserwave is 620-670 nm,
pulse width is 7 -+- nsec, pulse irradiation energy is
6 mJ/pulse, and repeated frequency is 50 Hz (Fig. 2).
Colposcope for Laser Therapy
Cervical Probe
This probe was developed to administer PDT in
the cervical canal, i.e., endocervix. A special sap-
phire chip or ceramic chip is mounted on the tip of
the cut fiber (Fig. 4).
Laser Power Distribution of the Cervical Probe
It can administer photoirradiation in a forward
direction on the cervical canal side walls: 70% of
RV CAL CANAL
A feature of the Olympus Laser Colposcope is an
optical path for the laser and allows cervical lesions
to be examined during photoirradiation. With this
method it is possible to show a 10mm circular spot
at the focus where the observation is made. This
results in stable and precise photoirradiation
(Fig. 3).
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FIGURE 3 Colposcope for laser therapy.186 T. MUROYA et al.
the laser light is scattered to the side walls and 30%
of the laser light forward. Thus, all of the cervical
canal can be irradiated (Fig. 5).
Cervical Probe Manipulator
Previously, the operator needed to mark the posi-
tion where the cervical probe was originally inserted
in order to withdraw in mm increments. Presently,
a cervical probe manipulator is installed in the
colposcope, and it can move 0.5mm in half rev-
olutions and mm in one complete revolution. This
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FIGURE 5 Laser power distribution of the cervical probe.
enables the operator to withdraw exactly mm
(Fig. 6).
Classification by Colposcopic Findings
According to the location of the lesions on the
uterine cervix, the results of PDT are divided into
the following three types:
Type I means that the second S-C Junction was
visible.
Type II means that the second S-C Junction was
not visible.
Type III means Uncertifiable Colposcopic
Findings.
As a rule, Type III cases were excluded fromPDT
because the irradiation would have been blind.
Preparations Before Irradiation
1. Check patient’s vital signs and confirm that
patient has finished urinating.
2. Patient should wear a cloth to cover entire body
and then proceed to the laser treatment room.
FIGURE 6 Cervical probe manipulator.PDT FOR CERVICAL CANCER 187
3. After putting on socks patient should get on table
and then use paper tape to fix bath towels to
minimize exposed areas.
4. Patient should cover genitals, other than the
parts for irradiation by using gauze, and fix it by
paper adhesive plaster.
5. Patient should wear sunglasses during the entire
treatment period.
6. Cusco speculum should be inserted in a manner
such that mobility is maintained, and fix the
position slightly so as not to slide.
7. After sterilization ofvagina using a disinfectant,
acetic acid should be applied.
Colposcope Irradiation (Spot Irradiation)
1. Lesions located at the uterine cervix should be
irradiated, particularly around the worst lesions
at an energy intensity rate of 100 J/cm
2 per shot
using an Olympus laser colposcope through
direct observation.
2. A large amount of cervical mucous is produced
by irradiation. It should be removed using swabs
or a cc syringe for cervical mucous extraction
whenever needed.
3. Spot irradiation should overlap without leaving
retention on the circumference. The pattern
should resemble Olympic Game logo.
4. Typically parts, uneven surfaces and angles such
as the cervical canal, should be irradiated in all
directions by carefully adjusting the Cusco spec-
ulum and changing the laser angle. (Especially
when glandular involvement exists, irradiation
needs to be thorough as it tends to leave areas
which have not been irradiated in such case.)
Cervical Canal Irradiation
After confirming the lesion is inside the cervical
canal by using a hysteroscope, the cervical probe
should be inserted to the required depth. Irradiation
should be repeated as the inserted fiber is drawn
from the cervical canal in mm increments till it
drops out from the external uterine orifice.
Administration of Patients After PHE Injection
Patients become extremely sensitive to sunshine
for about a week after PHE injection. When
exposed to intense light, the exposed skin reddens
andmay develop optic hyperesthesia such as edema.
Therefore, the patient’s room brightness should
be measured using a lux meter and the following
adjustments should be observed:
Patient should stay in the room with a bright-
ness of 10 lux immediately before the intraven-
ous injection.
After PHE injection, patient should stay in the
room with a brightness of 10 lux for 4 days.
From the 5th day after PHE injection, the
intensity should be 151ux, and patients should
be allowed to watch television.
From the 8th day after PHE injection, _< 30 lux.
From the lth day after PHE injection,
< 60 lux.
From the 16th day after PHE injection, <_ 80 lux.
From the 19th day afterPHE injection, _< 100 lux.
From the 20th day after PHE injection, the
restriction on the brightness is lifted and the
patient may leave the hospital after sunset on
that day.
Patient should use UV (ultra violet rays) screen
make-up cream and sun-shield cream as well as
the administrated room brightness. When going
out ofthe room, sunglasses, a hood, gloves, socks,
a scarf, and a long sleeve dress should be worn so
as not to be exposed to unnecessary light.
After leaving the hospital, patients are instructed to
be cautious, avoiding direct sunshine for prolonged
periods of time within two months after the PHE
injection. Extreme caution should be observedwhen
going outside at times when UV is stronger and
when there is a lot of sunshine. Patients are also
instructed to avoid intense direct sunshine for about
six months after the PHE injection.
Also, it is understood that patients who have been
exposed to sunlight from sunbathing before hospi-
talization are less likely to develop side effects than
patients who have not done so.188 T. MUROYA et al.
Evaluation of Effectiveness of PDT
Two months after PDT patients are checked by
cytological, colposcopic, histopathological findings,
and they are divided into the following four levels.
Patients classified below PR are re-examined four
months after PDT:
CR: All lesions are completely cured in terms of
cytological, colposcopic, and histopathological
findings.
PR: Almost all lesions are cured, but cytological,
colposcopic, and histopathological findings
suggest that some lesions may not yet be cured.
NC: Most lesions are not cured, and cytolog-
ical, colposcopic, and histopathological findings
before PDT and after PDT are almost the same.
Lesions from pre-PDT are completely preserved.
PD: Among cytological, colposcopic, and histo-
pathological findings, more than one finding
became worse than before PDT.
had complications, 17 patients refused to undergo
conventional surgery and 2 were elderly (Table I).
Studies using the PDT method have been con-
ducted on 131 patients (95 CIS, 31 dysplasia, and
recently 3 squamous cell carcinoma, microinvasion
(Fig. 7), and CIS + endocervical adenocarcinoma,
microinvasion, vulval dysplasia). Out of 131 cases,
127 became CR (96.9%). In addition, all micro-
invasive cases became CR. Only 4 cases showed any
remnants in a very limited area but most of the
lesions had disappeared (Table II). One PR case
became CR after a second PDT.
TABLE Age and Reason for PDT
RESULTS
In our practice, 85% of all patients who received
PDT wanted to preserve fertility. Only patient
FIGURE 7 S.C.C. Ia case before and after PDT (32 year old patient), upper left: low-power view; upper right: high-power
view; lower left: 11 weeks after PDT; lower right: 5 months after PDT.PDT FOR CERVICAL CANCER 189
TABLE II Response
Cases CR PR NC
Dysplasia
CIS
S.C.C. Ia
EC-Ad-ca Ia
VIN*
Total
31 30(96.8%) 1(3.2%) 0(0%)
95+ 92+ 1(96.88%) 2(2.08%) 1(1.04%)
3 3(lOO%) 0(0%) 0(0%)
1(100%) 0(0%) 0(0%)
1(100%) 0(0%) 0(0%)
131+ 127+ 1(96.97%) 3(2.27%) 1(0.75%)
*VIN (Vulvar Intraepitheliar Neoplasia).
Only NC case would have beenPR ifthe present
standard was applied then. Lesions evenly spread on
the vaginal wall were highly suspected to be invasive
cancer. After receiving PDT the patient became
pregnant and had a normal delivery. Subsequently,
since remnants were found in the deep cervical
canal, a semi-radical hysterectomy was performed.
Histopathological findings on the extracted
uteruses showed that the original lesions on the
vaginal wall and in the cervical canal had almost
disappeared, and the only remnant found was in
the deep internal cervical canal, where it was
suspected that the first PDT did not reach.
We found remnants only in the cervical canal in
PR case which was CIS. The remnants had
disappeared and became CR after a second PDT
was performed. Three and a half years have passed
after the second PDT, and so far there has been no
recurrence reported. One severe dysplasia and CIS
cases were PR. Some remnants within a very limited
area were seen after PDT and are still under
observation.
The first PDT was administered about nine years
ago. After PDT treatment 22 patients became
pregnant, and out of those patients, 12 had normal
transvaginal deliveries and 4 had cesarean sections
(due to the following reasons obstetrical procedures
were performed: one case had a cesarean section on
the first delivery; another was premature at eight
months; another case was CPD) and 3 are currently
pregnant and 3 have had abortions. In 3 cases even
a second child was born. They did not develop
any adhesion or constriction of the cervical canal,
and no difficulties were reported connected with
childbirth after PDT. Also, even where there were
stump remnants, in which a total hysterectomy is
usually required after cold knife conization, the
patient became CR after PDT and had a cesarean
section (patient had previously given birth by
cesarean section).
Side Effects
Side effects of PDT are similar to symptoms of
sunburn such as reddened skin due to sensitive
reaction to sunlight. But only 20 cases among 131
required treatment, and they improved the follow-
ing day after applying steroid ointment. In some
cases, in the summer, when skin is exposed to sun,
there was some incidence of skin irritation but
not s.erious. Applying calamine lotion relieved the
symptoms.
It is necessary to administer strict shading control
in order to avoid side effects from sunburn, but as
long as the shading time control is adhered to, there
has been almost no problem reported. No side
effects or abnormal findings have been recognized
in blood and urine tests.
DISCUSSION
One of the points which should be noted by
gynecologists is the increase in the trend ofyounger
patients who "want to preserve fertility. About 85%
ofourPDT patients wanted to preserve fertility, and
for that purpose preserving the uterus is critical. In
order to respond to these patients’ demands, PDT is
well suited since it leaves the cervix relatively intact.
PDT can be performed without anesthesia since
there is no pain. In addition, there is no bleeding
using PDT.
The recovery ratio after PDT is very high. No
difficulties have been experienced during childbirth
due to PDT, and further, transvaginal deliveries are
possible. Also, no negative effect on pregnancy and
the child have been reported. Such advantageous
points have been receiving a lot of attention. The
primary limitation of PDT is its similarity to190 T. MUROYA et al.
symptoms of sunburn. Our PDT is administrated
to relatively younger patients who are more con-
cerned about skin blemishes and spots. Strict
shading time should be observed by the patient.
Insofar as this point is kept, we have seen no
particular side effects as yet.
There are anumber ofpoints which can be cited as
reasons for the favorable results ofPDT. First, it is
possible to obtain a relatively accurate diagnosis
by cytological, colposcopic, and histopathological
findings before the therapy is administered. Second,
we use a pulse laser with a higher tissue penetration
capability. Third, now it is possible to have stable
and precise spot irradiation through direct observa-
tion using a colposcope equipped with an optical
path for a laser. Fourth, for cervical canal treatment
we use a cervical probe with the function to
administer photoirradiation to the entire cervical
canal. Thus, it became quite effective on glandular
involvement cases and improved the total CR ratio.
Both EDL and PHE (Photofrin(R)) have received
the approval ofthe Japanese Ministry ofHealth and
Welfare, and since April 1996, patients have been
covered by the Japanese national health insurance
program. Also, clinical trials of lasers with variable
laser wavelength (YAG-OPO; manufactured by
IHI) have commenced, and a new type of diode
laser has also been in the preparation stages for
clinical trials. These latest developments should
benefit and promise even more technological
advancements ofPDT in the future.
At the same time, due to the ongoing progress
and development of different photosensitizers
which have shorter retention time, shortening
the shading and hospitalization time has been
promised. First generation compounds, such as
PHOTOFRIN(R), require that the patient be hospi-
talized for a period from three weeks to two months
and necessitate strict shading. In the future we
expect that PDT can be performed without any
hospitalization using new photosensitizers such as
BPD-MA, ATX-S 10, and NPe6.
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